Najah Abi-Gerges1, Jean-Pierre Valentin, Chris E Pollard. 1. Safety Pharmacology Department, Safety Assessment UK, AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire, UK. najah.abigerges@astrazeneca.com
Abstract
BACKGROUND AND PURPOSE: Evaluation of the potential for delayed ventricular repolarization and proarrhythmia by new drugs is essential. We investigated if dog left ventricular midmyocardial myocytes (LVMMs) that can be used as a preclinical model to assess drug effects on action potential duration (APD) and whether in these cells, short-term variability (STV) or triangulation could predict proarrhythmic potential. EXPERIMENTAL APPROACH: Beagle LVMMs and Purkinje fibres (PFs) were used to record APs. Effects of six reference drugs were assessed on APD at 50% (APD(50)) and 90% (APD(90)) of repolarization, STV(APD), triangulation (ratio APD(90)/APD(50)) and incidence of early afterdepolarizations (EADs) at 1 and 0.5 Hz. KEY RESULTS: LVMMs provided stable recordings of AP, which were not affected by four sequential additions of dimethyl sulphoxide. Effects of dofetilide, d-sotalol, cisapride, pinacidil and diltiazem, but not of terfenadine, on APD in LVMMs were found to be comparable with those recorded in PFs. LVMMs, but not PFs, exhibited a proarrhythmic response to I(Kr) blockers. Incidence of EADs was not related to differences in AP prolongation or triangulation, but corresponded to beat-to-beat variability of repolarization, here quantified as STV of APD. CONCLUSIONS AND IMPLICATIONS: LVMMs provide a suitable preclinical model to assess the effects of new drugs on APD and also yield additional information about putative indicators of proarrhythmia that add value to an integrated QT/TdP risk assessment. Our findings support the concept that increased STV(APD) may predict drug-induced proarrhythmia.
BACKGROUND AND PURPOSE: Evaluation of the potential for delayed ventricular repolarization and proarrhythmia by new drugs is essential. We investigated if dog left ventricular midmyocardial myocytes (LVMMs) that can be used as a preclinical model to assess drug effects on action potential duration (APD) and whether in these cells, short-term variability (STV) or triangulation could predict proarrhythmic potential. EXPERIMENTAL APPROACH: Beagle LVMMs and Purkinje fibres (PFs) were used to record APs. Effects of six reference drugs were assessed on APD at 50% (APD(50)) and 90% (APD(90)) of repolarization, STV(APD), triangulation (ratio APD(90)/APD(50)) and incidence of early afterdepolarizations (EADs) at 1 and 0.5 Hz. KEY RESULTS: LVMMs provided stable recordings of AP, which were not affected by four sequential additions of dimethyl sulphoxide. Effects of dofetilide, d-sotalol, cisapride, pinacidil and diltiazem, but not of terfenadine, on APD in LVMMs were found to be comparable with those recorded in PFs. LVMMs, but not PFs, exhibited a proarrhythmic response to I(Kr) blockers. Incidence of EADs was not related to differences in AP prolongation or triangulation, but corresponded to beat-to-beat variability of repolarization, here quantified as STV of APD. CONCLUSIONS AND IMPLICATIONS: LVMMs provide a suitable preclinical model to assess the effects of new drugs on APD and also yield additional information about putative indicators of proarrhythmia that add value to an integrated QT/TdP risk assessment. Our findings support the concept that increased STV(APD) may predict drug-induced proarrhythmia.
Authors: W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond Journal: Cardiovasc Res Date: 2003-04-01 Impact factor: 10.787
Authors: Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Balázs Horváth; Ferenc Ruzsnavszky; Krisztina Váczi; János Magyar; Tamás Bányász; András Varró; Péter P Nánási Journal: Pflugers Arch Date: 2014-08-02 Impact factor: 3.657
Authors: L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos Journal: Br J Pharmacol Date: 2012-01 Impact factor: 8.739
Authors: P Champeroux; J Y Le Guennec; S Jude; C Laigot; A Maurin; M L Sola; J S L Fowler; S Richard; J Thireau Journal: Br J Pharmacol Date: 2016-01-14 Impact factor: 8.739
Authors: Tamás Hézső; Muhammad Naveed; Csaba Dienes; Dénes Kiss; János Prorok; Tamás Árpádffy-Lovas; Richárd Varga; Erika Fujii; Tanju Mercan; Leila Topal; Kornél Kistamás; Norbert Szentandrássy; János Almássy; Norbert Jost; János Magyar; Tamás Bányász; István Baczkó; András Varró; Péter P Nánási; László Virág; Balázs Horváth Journal: Sci Rep Date: 2021-05-05 Impact factor: 4.379
Authors: Csaba Lengyel; Andrea Orosz; Péter Hegyi; Zsolt Komka; Anna Udvardy; Edit Bosnyák; Emese Trájer; Gábor Pavlik; Miklós Tóth; Tibor Wittmann; Julius Gy Papp; András Varró; István Baczkó Journal: PLoS One Date: 2011-04-15 Impact factor: 3.240
Authors: P Champeroux; J Thireau; S Judé; C Laigot-Barbé; A Maurin; M L Sola; J S L Fowler; S Richard; J Y Le Guennec Journal: Br J Pharmacol Date: 2015-03-26 Impact factor: 8.739